TEVA•benzinga•
B of A Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $22
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 8, 2025 by benzinga